This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (17)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Paul A. Frymoyer, MD; Rose Giammarco, MD; Frederick M. Farrar, MD; Edward T. Schroeder, MD

Arch Intern Med. 1985;145(11):1991-1995.

Abstract
• We used technetium Tc 99m medronate (methylene diphosphonate) scanning in the treatment of seven patients with rhabdomyolysis. In three patients the intense, diffuse, symmetric nature of the scans was suggestive of an underlying metabolic muscle disorder. The scans defined the extent of the muscle injury in three patients and demonstrated muscle injury that was not initially suspected in two patients. The scan also demonstrated clinically unsuspected metastatic pulmonary and gastric calcifications in one patient. All scans showed evidence of renal dysfunction. In conclusion, these cases demonstrate that Tc 99m medronate scanning helps to define the extent and location of muscle injury in rhabdomyolysis, and that diffuse muscle uptake of Tc 99m medronate may be associated with metabolic muscle disease.

(Arch Intern Med 1985;145:1991-1995)

Author Affiliations
From the Departments of Medicine (Drs Frymoyer, Giammarco, and Schroeder) and Radiology (Dr Farrar), State University of New York, Upstate Medical Center, Syracuse.

Footnotes
Accepted for publication Feb 8, 1985.

Read before the 16th annual meeting of the American Society of Nephrology, Washington, DC, Dec 6, 1983.

Reprint requests to State University of New York—Upstate Medical Center, 750 E Adams St, Syracuse, NY 13210 (Dr Frymoyer).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?